Study Number:	C12006-01
Study Sex:	Male
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.7.5
Stat Version:	2023.02.27S

Study Number: C12006-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 2-(2H-benzotriazol-2-yl)-4,6-bis(1,1-dimethylpropyl)phenol
CAS Number: 25973-55-1

Date Report Requested: 04/13/2026
Time Report Requested: 15:53:25
Lab: Battelle

Male

		Treatment Groups (mg/kg)				
	Phase Day	**0**	**30**	**100**	**300**	**1000**
Urea Nitrogen (mg/dL)	SD 14	15.8 ± 0.7 (5) *	18.0 ± 0.9 (5)	18.8 ± 1.2 (5)	17.4 ± 0.4 (5)	19.6 ± 0.4 (5) *
Percent of Control			113.9	119.0	110.1	124.1
Creatinine (mg/dL)	SD 14	0.38 ± 0.02 (5)	0.40 ± 0.00 (5)	0.38 ± 0.02 (5)	0.40 ± 0.00 (5)	0.36 ± 0.02 (5)
Percent of Control			105.3	100.0	105.3	94.7
Glucose (mg/dL)	SD 14	142.6 ± 9.2 (5)	128.4 ± 9.9 (5)	124.2 ± 7.0 (5)	134.0 ± 7.8 (5)	117.2 ± 4.4 (5)
Percent of Control			90.0	87.1	94.0	82.2
Total Protein (g/dL)	SD 14	6.72 ± 0.14 (5)	6.50 ± 0.10 (5)	6.44 ± 0.19 (5)	6.60 ± 0.12 (5)	6.48 ± 0.07 (5)
Percent of Control			96.7	95.8	98.2	96.4
Globulin (g/dL)	SD 14	2.32 ± 0.09 (5) **	1.48 ± 0.04 (5) **	1.32 ± 0.08 (5) **	1.36 ± 0.09 (5) **	1.42 ± 0.06 (5) **
Percent of Control			63.8	56.9	58.6	61.2
A/G Ratio	SD 14	1.90 ± 0.05 (5) **	3.40 ± 0.07 (5) **	3.92 ± 0.16 (5) **	3.91 ± 0.23 (5) **	3.59 ± 0.15 (5) **
Percent of Control			178.4	205.6	205.5	188.4
Albumin (g/dL)	SD 14	4.40 ± 0.05 (5) **	5.02 ± 0.08 (5) **	5.12 ± 0.12 (5) **	5.24 ± 0.05 (5) **	5.06 ± 0.05 (5) **
Percent of Control			114.1	116.4	119.1	115.0
Cholesterol (mg/dL)	SD 14	121.2 ± 2.4 (5) **	89.0 ± 4.8 (5) **	81.0 ± 4.7 (5) **	93.0 ± 2.8 (5) **	83.0 ± 5.2 (5) **
Percent of Control			73.4	66.8	76.7	68.5
Triglyceride (mg/dL)	SD 14	97.8 ± 8.3 (5)	89.2 ± 8.1 (5)	95.4 ± 4.8 (5)	90.0 ± 4.8 (5)	72.6 ± 7.6 (5)
Percent of Control			91.2	97.5	92.0	74.2
Alanine Aminotransferase (IU/L)	SD 14	57.0 ± 1.9 (5) **	71.8 ± 5.2 (5) *	72.0 ± 4.7 (5) **	87.2 ± 10.6 (5) **	88.2 ± 4.5 (5) **
Percent of Control			126.0	126.3	153.0	154.7
Alkaline Phosphatase (IU/L)	SD 14	217.2 ± 13.7 (5) **	317.2 ± 34.2 (5) **	378.8 ± 12.7 (5) **	416.2 ± 27.3 (5) **	444.8 ± 24.4 (5) **
Percent of Control			146.0	174.4	191.6	204.8

Study Number: C12006-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 2-(2H-benzotriazol-2-yl)-4,6-bis(1,1-dimethylpropyl)phenol
CAS Number: 25973-55-1

Date Report Requested: 04/13/2026
Time Report Requested: 15:53:25
Lab: Battelle

Male

		Treatment Groups (mg/kg)				
	Phase Day	**0**	**30**	**100**	**300**	**1000**
Creatine Kinase (IU/L)	SD 14	167.0 ± 33.7 (4) **	168.4 ± 10.4 (5)	282.8 ± 96.4 (5)	316.4 ± 38.0 (5) **	434.6 ± 133.8 (5) **
Percent of Control			100.8	169.3	189.5	260.2
Sorbitol Dehydrogenase (IU/L)	SD 14	11.5 ± 1.6 (5)	14.8 ± 2.3 (5)	12.0 ± 1.0 (5)	12.5 ± 3.6 (5)	6.8 ± 1.7 (4)
Percent of Control			129.3	104.7	109.2	58.8
Bile salt/acids (µmol/L)	SD 14	26.4 ± 4.5 (5)	50.2 ± 2.8 (5)	68.2 ± 8.4 (5) **	37.2 ± 10.2 (5)	48.4 ± 9.5 (5)
Percent of Control			190.2	258.3	140.9	183.3

LEGEND

Values given as mean ± SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

SD = Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at p <= 0.05

** Statistically significant at p <= 0.01

SEM = Standard Error of the Mean

Clinical chemistry data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.

** END OF REPORT **